CUTISS AG secures CHF 25 million in series C

The funding enables progress to be made with denovoSkin™, a personalized skin therapy, and further automation technology for skin production. The startup plans to use the fresh funds to drive forward phase 3 trials.

Schlieren, Switzerland, May 2024 - CUTISS AG, a Swiss company in the field of skin regeneration and tissue engineering, has secured CHF 25 million in the first tranche of its Series C financing round. This investment will enable the company to make significant progress in the development and commercialization of its products.

Investors and plans

The financing round is led by the Giuliani family and a new US family represented by Shiloh Advisors AG. CUTISS will use the funds to advance Phase 3 trials for its personalized skin therapy denovoSkin™, which has achieved positive results in Phase 2. The funding will also support the further development and clinical preparation of the automated denovoSkin™ biomanufacturing machine. Furthermore, preparations are being made for the market launch of VitiCell®, a medical device for the treatment of vitiligo.

Securing the first CHF 25 million in our Series C financing round is a significant step for CUTISS

Dr. Daniela Marino, CEO and co-founder of CUTISS

CUTISS invites further investors to participate in the current Series C financing round. The company has so far received a total of CHF 92 million from private investors, family offices and public institutions. Supporters include Giammaria Giuliani, Zürcher Kantonalbank (ZKB), the Wyss Foundation and the Cherry Bay Capital Group. The company has also received grants from the European Union, Innosuisse and Wyss Zurich.

About the startup

CUTISS AG is a Swiss clinical-stage company specializing in regenerative medicine and skin tissue engineering. Its lead product denovoSkin™ is a bio-engineered, personalized skin graft that is in Phase III trials in Europe and has received orphan drug status for the treatment of burns from Swissmedic, EMA and FDA.

CUTISS is also developing machines to automate the production process of the personalized skin graft. The start-up was founded in 2017 as a spin-off of the University of Zurich (UZH) and the University Children's Hospital Zurich. Its headquarters are located in the Bio-Technopark in Zurich-Schlieren.